This refresh
Data-driven refresh July 10, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,236 tickers); 1,783 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $22.01 · 1Y $24.53 · 5Y $35.91 · 10Y $53.27
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.5x B+ · PEG 0.59 A-
Why now. Doximity is a high-quality growth compounder, leveraging its dominant digital platform and AI-powered workflow tools like Ask and Scribe to capture increasing ad spend from pharmaceutical manufacturers and health systems. With an impressive 30.4% profit margin and a 0.59 PEG ratio, DOCS generates substantial $326m in free cash flow annually against a lean 0.01 Debt-to-Equity, indicating robust financial health. The crux is its ability to maintain high engagement among medical professionals, making it an indispensable channel for sponsored content and professional tools.
Moat. Doximity's durable moat stems from its established network effect among medical professionals in the U.S., where its personalized newsfeed and HIPAA-compliant workflow tools like Ask and Scribe create high switching costs. This category leadership allows for exceptional profitability, evidenced by a 20.6% Return on Equity, as pharmaceutical manufacturers and health systems rely on Doximity's platform to reach a highly targeted and engaged audience. The specialized nature of its content and tools makes it difficult for new entrants to replicate its deep integration into clinical workflows.
Risk. The bear case hinges on Doximity's ability to sustain its growth trajectory amidst increasing competition for digital ad spend from pharmaceutical manufacturers and health systems. While profitable, the 13.1% revenue growth could be viewed as decelerating for a growth stock, especially with a P/E of 22.5, suggesting limited upside if growth stagnates. A concrete signal confirming the bear case would be a sustained decline in the adoption or monetization of its newer workflow tools like Ask and Scribe, indicating a weakening competitive position.
Horizon. 1-3 yr $24.53 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.91 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $53.27 if current growth sustains into durable earnings power.
2. INTU — Intuit Inc. · score 89.4
Software - Application · price $273.38 · 1Y $486.61 · 5Y $712.45 · 10Y $1,057
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.7x A- · PEG 0.71 A-
Why now. Intuit’s compounding engine is the seamless lock‑in of small‑business customers to the QuickBooks‑Mailchimp ecosystem, where cross‑selling of payroll, payments, financing and marketing drives recurring revenue. The business is expanding revenue at 15.6% YoY while delivering a 21.9% profit margin and generating $7.8 B of free cash flow, giving it the cash to reinvest and buy back shares. The thesis rests on the durability of this ecosystem‑wide stickiness, which should keep the growth‑rate and cash conversion high for the foreseeable future.
Moat. QuickBooks is the de‑facto accounting platform for U.S. SMBs, and its integration with payroll, merchant processing and financing creates a high‑cost switching barrier—once a business embeds these tools, migration is costly and disruptive. Mailchimp adds a marketing‑automation layer that deepens data integration, locking in the same customer base. This ecosystem, combined with a 22.2% ROE derived from pricing power in a captive market, is not easily replicated by new entrants.
Risk. The upside hinges on sustained double‑digit revenue growth; any slowdown—evidenced by the modest PE of 16.7x relative to a growth profile—could compress margins and erode cash flow. Competition from other cloud‑based accounting suites could siphon SMB customers, and the wide analyst target range ($275–$921) signals market uncertainty. A breach of the 52‑week high ($813.7) without corresponding earnings acceleration would confirm the valuation is overstretched and invalidate the compounding story.
Horizon. 1-3 yr $486.61 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $712.45 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,057 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 89.3
Software - Infrastructure · price $14.57 · 1Y $17.75 · 5Y $25.99 · 10Y $38.55
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.8x B+ · PEG 0.49 A
Why now. DLocal's robust payment processing services, particularly its pay-in solutions for global merchants expanding online, are driving exceptional growth by facilitating international and local cards, online bank transfers, and hundreds of alternative payment methods. The company's ability to handle complex cross-border and local-to-local transactions has fueled a remarkable 46.6% FY YoY revenue growth, while its 0.49 PEG ratio suggests this growth is significantly undervalued relative to its 22.8 P/E. The persistent demand for seamless global payment infrastructure across diverse end markets like commerce, streaming, and SaaS ensures continued compounding.
Moat. DLocal's competitive advantage stems from its comprehensive payment processing services that integrate hundreds of alternative payment methods (APMs) and manage complex cross-border and local-to-local transactions. This specialized infrastructure creates high switching costs for global merchants, as integrating such a diverse range of payment options is technically demanding and critical for expanding online presence. The impressive 34.6% ROE reflects the pricing power derived from being a critical, embedded partner in facilitating global commerce for sectors like streaming and ride-hailing.
Risk. The primary risk for DLocal lies in the intense competition within the global payment processing sector, particularly for cross-border and local-to-local transactions, which could pressure its impressive 18% profit margin. While growth is strong, any deceleration from the 46.6% FY YoY revenue growth rate could quickly re-rate its 22.8 P/E multiple downwards, especially given its exposure to emerging market payment complexities. A sustained decline in revenue growth below 30% for two consecutive quarters would confirm that competitive pressures are eroding its market position.
Horizon. 1-3 yr $17.75 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $25.99 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $38.55 if current growth sustains into durable earnings power.
4. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $91.09 · 1Y $104.75 · 5Y $153.37 · 10Y $227.51
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 14.3x A- · PEG 0.51 A-
Why now. Stride, Inc. is a compelling growth compounder, leveraging its integrated package of online curriculum and educational services to capture secular tailwinds in virtual and blended public schooling. The company's impressive 17.9% FY YoY revenue growth is translating directly to the bottom line, evidenced by a robust 12.2% profit margin and $414m in free cash flow. With a remarkably low 0.51 PEG ratio and a P/E of just 14.3, the market is significantly undervaluing its compounding power, which rests on the sustained adoption of its technology-based learning solutions.
Moat. Stride's durable edge stems from its comprehensive, integrated package of proprietary and third-party online curriculum, software systems, and educational services. By enabling clients to attract, enroll, educate, track progress, support, and facilitate individualized learning for students, Stride creates significant switching costs for schools and school districts. This deep integration into the operational fabric of virtual and blended public schools, coupled with its professional expertise, makes its offerings sticky and difficult for competitors to dislodge or replicate quickly.
Risk. The primary bear case for Stride centers on potential shifts in public education policy or funding that could curtail the expansion of virtual and blended learning environments, impacting demand for its core integrated services. While current growth is strong, the stock has seen a significant drawdown from its 52-week high of $171.17, suggesting market sensitivity to perceived changes in the online education landscape. A sustained deceleration in its 17.9% revenue growth rate, particularly if accompanied by margin compression, would confirm that the tailwinds for its online curriculum and educational services are weakening.
Horizon. 1-3 yr $104.75 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $153.37 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $227.51 if current growth sustains into durable earnings power.
5. ADBE — Adobe Inc. · score 89.2
Software - Application · price $222.65 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 12.7x A · PEG 0.60 A-
Why now. Adobe's robust free cash flow generation, evidenced by $10.3b TTM FCF against an $88.5b market cap, underpins its value as a growth compounder. The company's entrenched Digital Media and Digital Experience segments continue to drive a healthy 28.7% profit margin and 10.5% revenue growth. This strong cash generation, coupled with a remarkably low 0.6 PEG ratio, suggests significant undervaluation for a business with persistent demand for its essential creative and experience management tools.
Moat. Adobe's formidable moat stems from its category leadership and high switching costs within its integrated Digital Media and Digital Experience platforms. The essential nature of its tools for photographers, video editors, graphic designers, and marketers creates deep entrenchment, making it difficult for customers to migrate to alternatives. This persistent demand and pricing power are reflected in its exceptional 62.8% Return on Equity, demonstrating the company's ability to generate significant profit from its equity base.
Risk. Bears argue that Adobe's 10.5% FY YoY revenue growth is decelerating, signaling increasing competition or market saturation in its core Digital Media and Digital Experience segments. The stock's elevated 1.43 beta suggests it's highly sensitive to broader market downturns, amplifying risk for investors. A sustained period of single-digit revenue growth or a significant contraction in its 28.7% profit margin would confirm the bear case, indicating a loss of pricing power or increased competitive pressure.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87
Drug Manufacturers - Specialty & Generic · price $180.55 · 1Y $197.95 · 5Y $289.82 · 10Y $429.93
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 27.8x B · PEG 0.49 A
Why now. Neurocrine Biosciences is a compelling growth story, driven by its established portfolio led by INGREZZA for tardive dyskinesia and Huntington's chorea, alongside a robust pipeline targeting neurological and endocrine disorders. The company's impressive 21.4% revenue growth FY YoY, coupled with a healthy 21.6% profit margin and an exceptionally low 0.49 PEG ratio, indicates strong operational efficiency and undervaluation relative to its growth trajectory. The crux of the thesis rests on NBIX's ability to continue expanding market share for its commercialized products and successfully advance its clinical development candidates like NBI-1076986 and Osavampator.
Moat. Neurocrine Biosciences' durable edge stems from its specialized focus and intellectual property protecting key pharmaceutical assets like INGREZZA for tardive dyskinesia and chorea, and CRENESSITY for congenital adrenal hyperplasia. The high barriers to entry in discovering, developing, and commercializing treatments for complex neurological, psychiatric, endocrine, and immunological disorders create a significant moat. This specialized expertise and regulatory approvals for its product lines, combined with ongoing R&D in its clinical pipeline, ensure sustained market relevance and protect its strong 19.6% return on equity.
Risk. The primary bear case for Neurocrine Biosciences centers on potential pipeline setbacks and increasing competition in its specialized therapeutic areas. While the current P/E TTM of 27.8 is justified by strong growth, any failure in clinical development for candidates like NBI-1076986 or Osavampator, or the emergence of a superior competitor to INGREZZA, could significantly impact future revenue streams. The concrete signal confirming the bear case would be a sustained deceleration in revenue growth below its current 21.4% rate, indicating either pipeline failures or market share erosion for its commercialized products.
Horizon. 1-3 yr $197.95 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $289.82 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $429.93 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 86.9
Biotechnology · price $9.27 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 13.6x A- · PEG 0.69 A-
Why now. ADMA is a compelling growth story driven by its specialty plasma-derived biologics, particularly BIVIGAM and ASCENIV, addressing the critical need for primary humoral immunodeficiency (PI) treatments. The company boasts a phenomenal 32.4% profit margin and 42.4% ROE, translating into robust free cash flow of $108m (TTM) against a $2.1b market cap. The market is still underpricing this compounding growth, as evidenced by a low PEG ratio of 0.69, suggesting significant upside as its vertically integrated plasma collection centers continue to fuel manufacturing scale and market penetration.
Moat. ADMA's durable edge stems from its vertically integrated model, operating both ADMA BioManufacturing and Plasma Collection Centers, which ensures a controlled and consistent supply chain for its specialty plasma-derived biologics. The high ROE of 42.4% reflects the significant pricing power and demand for its critical IVIG products like BIVIGAM and ASCENIV, which treat primary humoral immunodeficiency (PI), a condition requiring long-term, specialized treatment. This integration and the specialized nature of its products create high barriers to entry and switching costs for patients and providers in the immune deficiencies and infectious diseases market.
Risk. The primary bear case centers on potential over-reliance on its core IVIG products for PI, BIVIGAM and ASCENIV, which could face intensified competition or pricing pressure in the specialty plasma-derived biologics market. Despite strong profitability, the debt-to-equity ratio of 1.11 indicates a leveraged balance sheet, which could become a concern if revenue growth (currently 19.6% FY YoY) decelerates or if capital expenditures for plasma collection centers increase significantly. A sustained decline in revenue growth below current levels, coupled with rising debt, would confirm the bear's thesis.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. EXLS — ExlService Holdings, Inc. · score 85.7
Information Technology Services · price $27.60 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 17.6x A- · PEG 0.87 B+
Why now. EXLS is a compelling growth compounder, leveraging its "data and artificial intelligence (AI)" capabilities to drive "digital operations and solutions" across critical sectors. Its robust 13.6% FY YoY revenue growth, combined with a highly efficient 11.7% profit margin and a low 0.87 PEG ratio, indicates a business effectively converting specialized services into shareholder value. The crux of the thesis rests on EXLS's deep integration into complex client workflows like "claims management" and "actuarial and risk analytics," ensuring sticky revenue streams as clients continue their digital transformation journeys.
Moat. EXLS's durable edge stems from its specialized "analytics-driven services" and deep domain expertise within its core segments: Insurance, Healthcare and Life Sciences, and Banking, Capital Markets, and Diversified Industries. By embedding solutions like "premium and benefit administration" and "underwriting support," EXLS creates high switching costs for clients. This specialized, mission-critical integration, coupled with its "data and AI" focus, allows the company to command pricing power, reflected in its exceptional 32.3% Return on Equity, far exceeding capital costs and making it difficult for generalist competitors to replicate.
Risk. The primary bear case centers on the intense competition within the "Information Technology Services" sector, especially as "digital operations and solutions" become more commoditized, potentially eroding EXLS's 11.7% profit margin. While EXLS boasts a strong growth profile, its current price of $27.6 is near its $24.85 52-week low, suggesting market skepticism about its ability to sustain premium pricing or differentiate its "AI" offerings against larger, more diversified players. A sustained deceleration in its 13.6% revenue growth, or a visible contraction in margins, would confirm the bear case and signal a loss of competitive edge.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
9. NVDA — NVIDIA Corporation · score 85.6
Semiconductors · price $202.78 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 31.1x B · PEG 0.60 A-
Why now. NVIDIA’s Compute & Networking data‑center AI platform is the single engine driving unstoppable compounding, as revenue surges 65.5% YoY, free cash flow tops $119.1 b, and ROE rockets to 81.7%. The AI‑centric accelerator stack locks in enterprise customers, turning each new model into a higher‑margin, higher‑cash‑flow engine. The thesis rests on the relentless expansion of AI workloads that only NVIDIA’s GPU‑plus‑software ecosystem can satisfy.
Moat. The Compute & Networking segment’s AI accelerators create massive switching costs—customers embed NVIDIA’s CUDA stack and DPX networking into their data‑center fabric, making migration prohibitively expensive. This pricing power fuels an 81.7% ROE, while a debt‑to‑equity of just 0.07 gives NVIDIA fiscal flexibility to reinvest in R&D and maintain its lead.
Risk. A 31.1× PE and a beta of 2.21 signal that the market has priced in near‑term AI exuberance; a slowdown in data‑center spend or a competitive breakthrough could compress margins and stall the 65.5% growth rate. The bear case crystallizes if quarterly revenue growth falls below 40% and the stock slides back toward its 52‑week low of $161.61.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
10. CPRX — Catalyst Pharmaceuticals, Inc. · score 84.6
Biotechnology · price $31.47 · 1Y $31.67 · 5Y $46.36 · 10Y $68.78
FCF $208m C · Rev +19.8% B+ · D/E 0.00 A · P/E 18.2x A- · PEG 0.92 B+
Why now. Catalyst Pharmaceuticals is a compelling growth compounder, leveraging its commercial-stage portfolio of rare disease treatments like Firdapse and Fycompa to drive consistent profitability. The company boasts impressive 19.8% FY YoY revenue growth and a robust 37.1% profit margin, while its 0.92 PEG ratio suggests that this growth is not yet fully priced in. The thesis hinges on Catalyst's ability to continue expanding its market penetration within the rare disease segment, ensuring persistent top-line expansion and free cash flow generation.
Moat. Catalyst's durable edge stems from its specialized focus on rare diseases, where treatments like Firdapse for LEMS and AGAMREE for duchenne muscular dystrophy address unmet medical needs with limited competition. This niche market leadership, coupled with regulatory approvals and intellectual property, grants significant pricing power, contributing to its strong 21.9% Return on Equity. Competitors face substantial hurdles in developing and commercializing alternative therapies for these specific, often orphan, indications.
Risk. The primary risk for Catalyst Pharmaceuticals lies in its concentration within a limited portfolio of rare disease drugs, specifically Firdapse, Fycompa, and AGAMREE. Despite a reasonable 18.2 P/E, any unexpected competitive entry or adverse clinical data for these key products could severely impact revenue and profitability, given the specialized nature of their markets. A material deceleration in revenue growth, particularly if driven by market share loss for its flagship LEMS treatment, would signal the bull thesis is breaking.
Horizon. 1-3 yr $31.67 (analyst consensus (n=3)) — fundamentals + valuation re-rating. 5 yr $46.36 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $68.78 if current growth sustains into durable earnings power.
11. IT — Gartner, Inc. · score 84.5
Information Technology Services · price $132.69 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.1x A · PEG 0.55 A-
Why now. Gartner represents a compelling growth opportunity, with its mission-critical Insights segment generating substantial free cash flow. A TTM P/E of just 13.1 and a remarkably low PEG Ratio of 0.55 suggest the market is significantly underpricing a business that produced $1.3b in free cash flow over the last twelve months. The crux lies in the persistent demand for its subscription-based business and technology insights, which compound value through recurring revenue streams.
Moat. Gartner's durable moat stems from its embedded position within client decision-making processes, particularly through its Insights segment's subscription services. Access to proprietary published content, data and benchmarks, and a direct network of business and technology experts creates high switching costs for organizations reliant on these mission-critical priorities. This deep integration and specialized knowledge are difficult for competitors to replicate quickly, ensuring recurring revenue and client stickiness.
Risk. The bear case argues that Gartner's growth trajectory is decelerating, with its revenue growth at a modest 3.7% (FY YoY), signaling potential market saturation or increased competition in its core business and technology insights. While the company offers mission-critical services, the significant drop from its 52-week high of $394.09 suggests investors are already pricing in a slowdown. A sustained trend of declining subscription renewals within the Insights segment or further contraction in its 11.4% profit margin would confirm the bear's concerns about its long-term compounding ability.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.9
Information Technology Services · price $87.29 · 1Y $142.82 · 5Y $209.11 · 10Y $310.20
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 12.5x A · PEG 0.45 A
Why now. EPAM is a deeply undervalued growth compounder in digital transformation, trading at a steep discount despite robust free cash flow generation. Its core offerings in digital platform engineering and cloud services are driving strong demand, evidenced by $544m in TTM FCF against a $4.6b market cap, implying a significant FCF yield, while revenue growth remains a healthy 15.4% FY YoY. The market is overlooking its consistent cash generation and growth potential in critical IT services, setting the stage for a significant re-rating as demand for digital transformation persists.
Moat. EPAM's deep expertise across complex engineering services, from requirements analysis to cross-platform migration and integration, creates high switching costs for clients. Its comprehensive suite of offerings, including data, analytics, artificial intelligence, and cybersecurity, allows it to embed deeply into client operations, making it difficult for competitors to displace. This integrated approach to digital platform engineering and smart automation services fosters long-term client relationships, protecting its revenue streams.
Risk. The high beta of 1.43 suggests EPAM is highly sensitive to broader economic downturns or a slowdown in enterprise IT spending, particularly in its digital platform engineering and software development segments. Despite its growth, the current profit margin of 7% indicates that any pricing pressure or increased competition in cloud services or AI could significantly erode profitability. A sustained deceleration in revenue growth below the current 15.4% or a further contraction in profit margins would confirm that competitive pressures or a cyclical downturn are impacting its core business.
Horizon. 1-3 yr $142.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $209.11 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $310.20 if current growth sustains into durable earnings power.
13. DXCM — DexCom, Inc. · score 83.1
Medical Devices · price $73.02 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 31.3x B · PEG 1.35 B
Why now. DexCom is a high-quality compounder leveraging its market-leading CGM systems like G7 and G6 to penetrate the massive diabetes and metabolic health market, now significantly expanded by the Stelo biosensor for non-insulin users. This strategic expansion is driving robust top-line growth of 15.6% (FY YoY) and translating into impressive profitability with a 19.3% profit margin and $1.4B in TTM free cash flow. The crux of the thesis rests on DexCom's ability to convert this expanding total addressable market into sustained, high-margin revenue growth.
Moat. DexCom's durable edge stems from its proprietary continuous glucose monitoring (CGM) technology, exemplified by its integrated G7 and G6 systems, which create significant switching costs for both patients and healthcare providers. This technological leadership and established direct distribution network to endocrinologists and physicians enable pricing power and contribute to its exceptional 31.5% Return on Equity. The company's consistent innovation, like the Stelo biosensor, further solidifies its position by expanding into new patient segments and reinforcing its intellectual property moat.
Risk. The bear case centers on DexCom's premium valuation, with a P/E TTM of 31.3 and a P/S TTM of 5.8, leaving little room for error in a competitive medical device landscape. While the company has successfully expanded its product portfolio with Stelo, increased competition in the broader diabetes and metabolic health market could pressure pricing and slow the adoption of its G7 and G6 systems. A sustained deceleration in revenue growth below the current 15.6% (FY YoY) would confirm the bear's concerns and likely trigger a significant re-rating of the stock.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
14. CARG — CarGurus, Inc. · score 82.8
Auto & Truck Dealerships · price $34.50 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 18.2x B · PEG 1.08 B+
Why now. CarGurus is a high-quality compounder leveraging its established online automotive marketplace to drive robust financial performance. The company's ability to connect a large audience of car shoppers with an extensive network of dealers, monetized through dealer subscription fees and advertising, fuels strong growth. This is evident in its healthy 13.7% FY YoY revenue growth, a substantial 15.9% profit margin, and impressive $293m in TTM free cash flow, indicating efficient operations and significant cash generation. The crux of the thesis rests on the persistent network effect between shoppers and dealers, continuously enhanced by its integrated suite of products like Digital Deal.
Moat. CARG's durable edge stems from the powerful network effect inherent in its online automotive marketplace, which connects a large audience of car shoppers with an extensive network of dealers. This two-sided platform creates high switching costs for both consumers and dealers, making it difficult for new entrants to replicate. The company's exceptional 62.9% Return on Equity is a direct result of its pricing power derived from this category leadership and the deep integration of its digital solutions, such as Dealership Mode, into the vehicle purchase process.
Risk. The primary risk for CarGurus lies in the potential for increased competition within the online automotive platform space and the cyclical nature of auto sales, which could pressure its core dealer subscription fees. While growth is solid, a debt-to-equity ratio of 0.79 and a beta of 1.18 suggest some financial leverage and market volatility, respectively, that could be exacerbated by a downturn in the auto market. A sustained decline in the growth rate of its dealer network or a significant contraction in average revenue per dealer would confirm the bear case and challenge the bull thesis.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82.2
Health Information Services · price $189.70 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 33.6x C+ · PEG 0.87 B+
Why now. Veeva Systems represents a compelling growth opportunity, leveraging its dominant position in cloud-based software for the life sciences industry. The company's specialized offerings like the Veeva Commercial Cloud and Veeva Data Cloud drive consistent expansion, evidenced by 16.3% FY YoY revenue growth and a robust 28.4% profit margin. With a PEG ratio of just 0.87, VEEV is trading at a discount to its growth prospects, suggesting significant upside as its mission-critical solutions continue to compound value within its specialized end market.
Moat. Veeva's durable competitive advantage stems from its deeply embedded, specialized cloud-based software tailored exclusively for the life sciences industry. Products like the Veeva Vault CRM Suite and Veeva PromoMats become mission-critical infrastructure for pharmaceutical and biotechnology companies, creating high switching costs and fostering long-term customer relationships. This vertical-specific focus and comprehensive suite of solutions, from commercial to data platforms, ensures continued market leadership and revenue predictability.
Risk. The primary bear case for Veeva centers on potential deceleration in its core life sciences cloud software market, particularly if pharmaceutical and biotechnology companies tighten spending on commercial or data solutions. Despite a healthy 16.3% revenue growth, the current P/E of 33.6 leaves little room for error if growth rates falter, especially after the stock's significant decline from its 52-week high of $310.5. A sustained trend of decelerating revenue growth below current levels would confirm the bear thesis, indicating market saturation or increased competitive pressure on its specialized product lines.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. RMD — ResMed Inc. · score 81.8
Medical Instruments & Supplies · price $208.45 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 20.1x B+ · PEG 1.28 B
Why now. ResMed is a high-quality compounder in the critical medical device market for respiratory disorders, delivering robust profitability and free cash flow at a reasonable growth valuation. The company's focus on diagnosing and treating sleep apnea with devices like ApneaLink Air and cloud-based software drives consistent 9.8% revenue growth and an impressive 27.4% profit margin. With $1.8B in free cash flow against a $30.2B market cap, the business generates substantial cash, which is key to its persistent earnings growth.
Moat. RMD's durable edge stems from its category leadership in sleep apnea diagnosis and treatment devices, such as ApneaLink Air and NightOwl, integrated with its cloud-based software applications. This comprehensive ecosystem creates significant switching costs for sleep clinics, hospitals, and home users, who rely on RMD for managing respiratory disorders. This deep integration and customer stickiness are fundamental drivers of RMD's exceptional 23.4% Return on Equity, reflecting strong pricing power and a difficult-to-replicate market position.
Risk. While RMD operates in a secular growth market, the moderate 9.8% revenue growth rate, coupled with a 20.1 P/E ratio, suggests that the market may already be pricing in much of its future growth potential. The significant drop from its 52-week high of $293.81 to the current $208.45 indicates investor concerns about growth deceleration or competitive pressures in its core Sleep and Breathing Health segment. A sustained deceleration in revenue growth below its current pace, or a material erosion of the 27.4% profit margin due to increased competition for its diagnostic devices, would confirm the bear case.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 81.4
Education & Training Services · price $131.32 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 19.1x B · PEG 0.88 B+
Why now. Covista’s Chamberlain University online nursing and health‑profession programs are the engine of compounding earnings, delivering 12.9% FY YoY revenue growth, $336m of free cash flow, and a sub‑1.0 PEG ratio of 0.88 that signals undervalued growth; the combination of a solid 12.3% profit margin and a low‑beta defensive profile means the compounding runway is anchored in a sector‑wide shortage of qualified health workers. The thesis rests on the persistence of that enrollment tailwind.
Moat. Covista’s moat comes from its three‑segment model—Chamberlain, Walden, and Medical & Veterinary—each delivering accredited, online degree pathways that lock in students for multi‑year programs and tie tuition to professional licensure, creating high switching costs. The 17.2% ROE reflects pricing power in a niche where few competitors can match Covista’s integrated curriculum, accreditation network, and government‑approved clinical placement infrastructure, making replication costly and slow.
Risk. The bear case hinges on regulatory headwinds in health‑profession education that could curb enrollment, while the company’s 0.54 debt‑to‑equity ratio leaves limited cushion if funding costs rise; a P/E of 19.1, though reasonable, is already priced for continued growth, so any slowdown below the 12.9% revenue pace would compress multiples and could push the stock toward its 52‑week low of $86.97. A sustained drop in enrollment or tighter accreditation standards would confirm the downside.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. META — Meta Platforms, Inc. · score 80.9
Internet Content & Information · price $631.48 · 1Y $828.17 · 5Y $1,213 · 10Y $1,799
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 23.0x B · PEG 0.87 B+
Why now. Meta Platforms is a high-quality compounder, delivering robust growth at a reasonable valuation. The Family of Apps (FoA) segment, encompassing Facebook, Instagram, and Messenger, continues to drive impressive 22.2% revenue growth and generate substantial $48.3B in free cash flow, while trading at a P/E of just 23. This combination of strong top-line expansion and efficient cash generation, reflected in a PEG ratio of 0.87, underscores the persistent compounding power derived from its massive, engaged user base.
Moat. Meta's durable edge stems from the formidable network effects embedded within its Family of Apps (FoA) segment, including Facebook, Instagram, and Messenger. The sheer scale of connections and shared content creates high switching costs and a self-reinforcing loop of user engagement, making it incredibly difficult for competitors to replicate. This deep user entrenchment translates directly into significant pricing power for advertisers, underpinning a stellar 29% Return on Equity.
Risk. The primary bear case for Meta centers on the substantial, long-term investment in the Reality Labs (RL) segment, which develops virtual reality (VR) headsets and AI glasses, posing a considerable drag on overall profitability if adoption remains slow or competitive. While the FoA segment is strong, the company's 1.25 beta indicates higher market sensitivity, and a P/S of 7.5 implies expectations for continued growth that could be challenged by sustained deceleration in core advertising revenue or escalating losses in RL. A clear signal confirming the bear case would be a prolonged period of declining user engagement across the FoA coupled with an inability for Reality Labs to demonstrate a viable path to profitability.
Horizon. 1-3 yr $828.17 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,213 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,799 if current growth sustains into durable earnings power.
19. QCOM — QUALCOMM Incorporated · score 79.8
Semiconductors · price $191.11 · 1Y $216.55 · 5Y $317.05 · 10Y $470.32
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 C+ · P/E 20.6x B+ · PEG 0.59 A-
Why now. QUALCOMM is a compelling growth compounder, leveraging its foundational wireless technology into burgeoning markets like automotive systems for ADAS/AD and IoT edge networking products, driving robust expansion beyond its mobile core. With a healthy 13.7% FY YoY revenue growth and a remarkably low 0.59 PEG ratio, the market is underpricing its consistent profitability, evidenced by a 22.3% profit margin. The crux is QCOM's strategic expansion into these high-value, high-growth adjacent segments, which promises to sustain its compounding trajectory.
Moat. QCOM's durable edge stems from its deep intellectual property portfolio, managed by the QTL segment, which grants licenses for foundational wireless technologies essential across the industry. This IP creates significant barriers to entry and high switching costs for customers embedded in its integrated circuits and system software for mobile, automotive, and IoT applications. The exceptional 36.4% Return on Equity reflects QCOM's pricing power derived from its category leadership in these critical, proprietary connectivity and computing technologies.
Risk. The primary risk for QUALCOMM lies in its exposure to cyclicality and intense competition within its core QCT segment, particularly in mobile devices, which could face pricing pressure or slowing demand. The company's elevated Beta of 1.64 indicates significant sensitivity to broader market downturns, amplifying potential losses if growth falters. A concrete signal confirming the bear case would be a sustained deceleration in overall revenue growth below the current 13.7% FY YoY, coupled with a contraction in its 22.3% profit margin, signaling a loss of pricing power or market share.
Horizon. 1-3 yr $216.55 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $317.05 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $470.32 if current growth sustains into durable earnings power.
20. MELI — MercadoLibre, Inc. · score 79.5
Internet Retail · price $1807.83 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 47.8x C · PEG 1.11 B+
Why now. MercadoLibre is a high-quality compounder, poised for continued expansion as its integrated e-commerce and financial technology ecosystem captures increasing market share in Latin America. The company's robust 34.3% FY YoY revenue growth, combined with a healthy 8.6% profit margin and impressive $11.8b in free cash flow, demonstrates its ability to scale profitably. The core thesis rests on the persistent network effects between Mercado Libre Marketplace and Mercado Pago, which continue to deepen user engagement and expand the total addressable market.
Moat. MELI's durable edge stems from the powerful network effect created by its comprehensive ecosystem, where Mercado Libre Marketplace drives traffic to Mercado Pago, and Mercado Pago's financial technology services (including Mercado Fondo and Mercado Credito) enhance user stickiness and facilitate transactions. This integration creates high switching costs for users and sellers, making it difficult for competitors to replicate the full suite of services. The company's 26.4% ROE is a direct result of this category leadership and the efficient monetization of its vast user base across both commerce and fintech segments.
Risk. The primary risk to MELI lies in the intense competitive landscape within the Internet Retail sector and the potential for increased regulatory scrutiny on its rapidly expanding financial technology solutions like Mercado Pago and Mercado Credito. With a P/E TTM of 47.8, the market has priced in substantial future growth, making the stock highly sensitive to any deceleration from its current 34.3% revenue growth rate. A sustained decline in profit margin from 8.6% or a significant increase in its 1.7 debt-to-equity ratio would confirm a weakening competitive position or increased operational strain.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
21. PODD — Insulet Corporation · score 79.5
Medical Devices · price $158.29 · 1Y $239.42 · 5Y $350.53 · 10Y $519.99
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 37.0x C+ · PEG 1.41 B
Why now. Insulet's Omnipod platform, spearheaded by the innovative Omnipod 5 automated insulin delivery system, continues to capture significant market share, driving exceptional top-line expansion. The company's 30.7% FY YoY revenue growth is translating into strong profitability, evidenced by a 23.2% Return on Equity and robust $416m in TTM Free Cash Flow. This compounding growth, fueled by increasing adoption of its user-friendly insulin delivery systems for insulin-dependent diabetes, underpins a compelling long-term investment thesis.
Moat. Insulet's competitive moat is built on its differentiated Omnipod platform, particularly the Omnipod 5's proprietary AID algorithm embedded directly in the pod, which simplifies insulin management for users. This integrated, user-friendly technology creates significant switching costs and fosters strong customer loyalty, contributing directly to the company's impressive 23.2% Return on Equity. The continuous innovation in its insulin delivery systems, like the Omnipod DASH, further solidifies its position in the insulin-dependent diabetes market.
Risk. Despite its growth, Insulet's valuation remains a concern for skeptics, with a TTM P/E of 37 reflecting high expectations that could be vulnerable to any deceleration in Omnipod 5 adoption or increased competitive pressure. The company's 1.11 beta also indicates higher volatility, suggesting that any market-wide downturn or specific competitive innovation in automated insulin delivery systems could disproportionately impact the stock. A sustained slowdown in revenue growth below 20% would be the clearest signal that the bull thesis is breaking.
Horizon. 1-3 yr $239.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $350.53 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $519.99 if current growth sustains into durable earnings power.
22. FIVE — Five Below, Inc. · score 78.8
Specialty Retail · price $184.24 · 1Y $260.57 · 5Y $328.97 · 10Y $421.89
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.2x B · PEG 0.98 B+
Why now. Specialty Retail · market cap $10.2b. Down 27% from 52-week high of $251.63 — deep drawdown territory. Revenue growing +23%, comfortably above the S&P median. PEG 0.98 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $260.57 (implying +41% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $260.57 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $328.97 at ~12% CAGR — dividend + buyback compounding. 10 yr $421.89 if the moat survives secular pressure.
23. DECK — Deckers Outdoor Corporation · score 78.5
Footwear & Accessories · price $104.26 · 1Y $126.86 · 5Y $160.15 · 10Y $205.39
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.9x B+ · PEG 1.32 B
Why now. Footwear & Accessories · market cap $14.5b. 18% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +22% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $160.15 at ~9% CAGR — dividend + buyback compounding. 10 yr $205.39 if the moat survives secular pressure.
24. NFLX — Netflix, Inc. · score 77.6
Entertainment · price $75.47 · 1Y $113.71 · 5Y $166.49 · 10Y $246.97
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 24.3x B · PEG 1.49 B
Why now. Entertainment · market cap $317.8b. Down 41% from 52-week high of $128.96 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $113.71 (implying +51% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $317.8b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.52 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $113.71 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $166.49 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $246.97 if current growth sustains into durable earnings power.
25. DEO — Diageo plc · score 75.7
Beverages - Wineries & Distilleries · price $80.61 · 1Y $100.43 · 5Y $147.04 · 10Y $218.12
FCF n/a · Rev +4.8% C+ · D/E 1.77 C · P/E 18.6x B+ · PEG 0.80 A-
Why now. Beverages - Wineries & Distilleries · market cap $44.8b. Down 31% from 52-week high of $116.41 — deep drawdown territory. PEG 0.80 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $100.43 (implying +25% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Dividend payout 96% of earnings on a 4.0% yield — distribution coverage is thin; one earnings stumble could force a dividend cut.
Horizon. 1-3 yr $100.43 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $147.04 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $218.12 if current growth sustains into durable earnings power.
26. FISV — Fiserv, Inc. · score 75.7
Sector n/a · price $51.65 · 1Y $69.77 · 5Y $88.08 · 10Y $112.96
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.8x A- · PEG 2.43 C
Why now. Sector n/a · market cap $27.5b. Down 70% from 52-week high of $171.08 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $69.77 (implying +35% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 70% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $69.77 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.08 at ~11% CAGR — dividend + buyback compounding. 10 yr $112.96 if the moat survives secular pressure.
27. ULTA — Ulta Beauty, Inc. · score 74.8
Specialty Retail · price $460.24 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +9.7% B · D/E 0.89 B · P/E 17.3x B+ · PEG 1.57 C+
Why now. Specialty Retail · market cap $19.8b. Down 36% from 52-week high of $714.97 — deep drawdown territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +35% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
28. YUMC — Yum China Holdings, Inc. · score 74.8
Restaurants · price $42.31 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +4.4% C+ · D/E 0.38 A- · P/E 16.2x B+ · PEG 1.06 B+
Why now. Restaurants · market cap $14.6b. Down 28% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +45% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
29. CVNA — Carvana Co. · score 74.4
Auto & Truck Dealerships · price $67.12 · 1Y $92.14 · 5Y $134.91 · 10Y $200.12
FCF $740m C+ · Rev +48.6% A · D/E 1.21 B · P/E 38.8x C · PEG 0.80 A-
Why now. Auto & Truck Dealerships · market cap $73.6b. Down 31% from 52-week high of $97.38 — deep drawdown territory. Revenue growing +49% — in hypergrowth territory. PEG 0.80 — paying under fair value for the growth rate. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $92.14 (implying +37% upside).
Moat. ROE 39% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $73.6b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 3.46 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $92.14 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $134.91 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $200.12 if current growth sustains into durable earnings power.
30. EME — EMCOR Group, Inc. · score 73.6
Engineering & Construction · price $783.41 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +16.6% B+ · D/E 0.13 A- · P/E 26.3x B · PEG 0.42 A
Why now. Engineering & Construction · market cap $34.9b. 18% off the 52-week high of $951.96. Revenue growing +17%, comfortably above the S&P median. PEG 0.42 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +28% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.